Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system

[1]  信澤 純人.  Molecular classification of low-grade diffuse gliomas , 2012 .

[2]  G. Reifenberger,et al.  Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic? , 2011, Clinical Cancer Research.

[3]  O. Chinot,et al.  Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis , 2010, Acta Neuropathologica.

[4]  G. Reifenberger,et al.  Molecular diagnostics of gliomas: state of the art , 2010, Acta Neuropathologica.

[5]  Martin J. Bent,et al.  Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta Neuropathologica.

[6]  H. Armah.  Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile , 2010 .

[7]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[8]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Fisher,et al.  Adult supratentorial low-grade glioma: long-term experience at a single institution. , 2009, International journal of radiation oncology, biology, physics.

[10]  M. J. van den Bent,et al.  IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide , 2009, Neurology.

[11]  H. Zentgraf,et al.  Monoclonal antibody specific for IDH1 R132H mutation , 2009, Acta Neuropathologica.

[12]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[14]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[15]  Frank M. Sacks,et al.  IDH 1 and IDH 2 Mutations in Gliomas , 2009 .

[16]  Dominique Figarella-Branger,et al.  Classification histologique et moléculaire des gliomes , 2008 .

[17]  M. Rosenblum,et al.  Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas , 2008, Journal of Neuro-Oncology.

[18]  D. Figarella-Branger,et al.  [Histological and molecular classification of gliomas]. , 2008, Revue neurologique.

[19]  M. Weller,et al.  Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker? , 2007, Clinical Cancer Research.

[20]  Webster K. Cavenee,et al.  Erratum: The 2007 WHO classification of tumours of the central nervous system (Acta Neuropathol (2007) vol. 114 (97-109)) , 2007 .

[21]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[22]  Caterina Giannini,et al.  Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome , 2007, Journal of neuropathology and experimental neurology.

[23]  Laurent Capelle,et al.  Dynamic history of low‐grade gliomas before and after temozolomide treatment , 2007, Annals of neurology.

[24]  E. Shaw,et al.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.

[25]  L. Mariani,et al.  Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Peraud,et al.  Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma , 2004, Cancer.

[27]  O. Chinot,et al.  Deletions of Chromosomes 1p and 19q are Detectable on Frozen Smears of Gliomas by FISH: Usefulness for Stereotactic Biopsies , 2004, Journal of Neuro-Oncology.

[28]  R. Fimmers,et al.  Oligodendroglial Tumors: Refinement of Candidate Regions on Chromosome Arm 1p and Correlation of 1p/19q Status with Survival , 2004, Brain pathology.

[29]  K. Roth,et al.  Prognostic Value of 1p, 19q, 9p, 10q, and EGFR‐FISH Analyses in Recurrent Oligodendrogliomas , 2004, Journal of neuropathology and experimental neurology.

[30]  D. Horsman,et al.  Loss of Heterozygosity for Loci on Chromosome Arms 1p and 10q in Oligodendroglial Tumors: Relationship to Outcome and Chemosensitivity , 2003, Journal of Neuro-Oncology.

[31]  A. Korshunov,et al.  Immunohistochemical Markers for Prognosis of Oligodendroglial Neoplasms , 2002, Journal of Neuro-Oncology.

[32]  H. Koga,et al.  Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry , 1994, Acta Neuropathologica.

[33]  M. J. van den Bent,et al.  Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.

[34]  E. Ricevuto,et al.  High sensitivity of detection of TP53 somatic mutations by fluorescence‐assisted mismatch analysis , 2002, Genes, chromosomes & cancer.

[35]  P. Kleihues,et al.  Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  B. Scheithauer,et al.  Mapping of the chromosome 19 q‐arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers , 2000, Genes, chromosomes & cancer.

[37]  L. Påhlman,et al.  Prognostic value of p53 genetic changes in colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D K Pearl,et al.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.